{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:08:18Z","timestamp":1787508498148,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40801-025-00486-x","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T08:26:07Z","timestamp":1741940767000},"page":"165-173","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-Term Evaluation of Effectiveness and Immunological Implications of Ocrelizumab in a Real-World Cohort"],"prefix":"10.1007","volume":"12","author":[{"given":"Tommaso","family":"Guerra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Paolicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2308-1731","authenticated-orcid":false,"given":"Pietro","family":"Iaffaldano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"issue":"7","key":"486_CR1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","volume":"17","author":"MT Cencioni","year":"2021","unstructured":"Cencioni MT, Mattoscio M, Magliozzi R, Bar-Or A, Muraro PA. B cells in multiple sclerosis: from targeted depletion to immune reconstitution therapies. Nat Rev Neurol. 2021;17(7):399\u2013414.","journal-title":"Nat Rev Neurol"},{"key":"486_CR2","doi-asserted-by":"publisher","first-page":"1004795","DOI":"10.3389\/fimmu.2023.1004795","volume":"14","author":"J de S\u00e8ze","year":"2023","unstructured":"de S\u00e8ze J, Maillart E, Gueguen A, et al. Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic. Front Immunol. 2023;14:1004795.","journal-title":"Front Immunol"},{"issue":"3","key":"486_CR3","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.3390\/ijms24032336","volume":"24","author":"G Kumar","year":"2023","unstructured":"Kumar G, Axtell RC. Dual role of B cells in multiple sclerosis. Int J Mol Sci. 2023;24(3):2336.","journal-title":"Int J Mol Sci"},{"key":"486_CR4","doi-asserted-by":"publisher","unstructured":"Filippi M, Amato MP, Centonze D, et al. Early use of high-efficacy disease\u2011modifying therapies makes the difference in people with multiple sclerosis: an expert opinion [published correction appears in J Neurol. 2022 Dec;269(12):6690\u20131. https:\/\/doi.org\/10.1007\/s00415-022-11385-4]. J Neurol. 2022;269(10):5382\u201394.","DOI":"10.1007\/s00415-022-11385-4"},{"key":"486_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221\u201334.","journal-title":"N Engl J Med"},{"key":"486_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209\u201320.","journal-title":"N Engl J Med"},{"key":"486_CR7","doi-asserted-by":"publisher","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","volume":"95","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Kappos L, Arnold DL, Bar-Or A, Brochet B, Naismith RT, et al. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology. 2020;95:e1854\u201367.","journal-title":"Neurology"},{"key":"486_CR8","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S1474-4422(20)30342-2","volume":"19","author":"JS Wolinsky","year":"2020","unstructured":"Wolinsky JS, Arnold DL, Brochet B, Hartung HP, Montalban X, Naismith RT, et al. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2020;19:998\u20131009.","journal-title":"Lancet Neurol"},{"issue":"3","key":"486_CR9","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/acn3.51732","volume":"10","author":"X Montalban","year":"2023","unstructured":"Montalban X, Matthews PM, Simpson A, et al. Real-world evaluation of ocrelizumab in multiple sclerosis: a systematic review. Ann Clin Transl Neurol. 2023;10(3):302\u201311. https:\/\/doi.org\/10.1002\/acn3.51732.","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"486_CR10","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1007\/s13311-022-01252-5","volume":"19","author":"M Margoni","year":"2022","unstructured":"Margoni M, Preziosa P, Tortorella P, Filippi M, Rocca MA. Does ocrelizumab limit multiple sclerosis progression? Current evidence from clinical, MRI, and fluid biomarkers. Neurotherapeutics. 2022;19(4):1216\u201328.","journal-title":"Neurotherapeutics"},{"issue":"7","key":"486_CR11","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1177\/13524585221147635","volume":"29","author":"G Abbadessa","year":"2023","unstructured":"Abbadessa G, Miele G, Maida E, et al. Immunomodulatory effects of ocrelizumab and candidate biomarkers for monitoring treatment response in multiple sclerosis. Mult Scler. 2023;29(7):779\u201388.","journal-title":"Mult Scler"},{"issue":"5","key":"486_CR12","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s10072-022-06582-y","volume":"44","author":"S Saidha","year":"2023","unstructured":"Saidha S, Bell J, Harold S, et al. Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis. Neurol Sci. 2023;44(5):1515\u201332.","journal-title":"Neurol Sci"},{"issue":"3","key":"486_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/WCO.0000000000001057","volume":"35","author":"M Trojano","year":"2022","unstructured":"Trojano M, Kalincik T, Iaffaldano P, Amato MP. Interrogating large multiple sclerosis registries and databases: what information can be gained? Curr Opin Neurol. 2022;35(3):271\u20137.","journal-title":"Curr Opin Neurol"},{"issue":"11","key":"486_CR14","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1007\/s10072-023-06876-9","volume":"44","author":"P Mosconi","year":"2023","unstructured":"Mosconi P, Guerra T, Paletta P, et al. Data monitoring roadmap: the experience of the Italian Multiple Sclerosis and Related Disorders Register. Neurol Sci. 2023;44(11):4001\u201311.","journal-title":"Neurol Sci"},{"key":"486_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.875456","volume":"13","author":"T Akaishi","year":"2022","unstructured":"Akaishi T, Ishii T, Aoki M, Nakashima I. Calculating and comparing the annualized relapse rate and estimating the confidence interval in relapsing neurological diseases. Front Neurol. 2022;13: 875456.","journal-title":"Front Neurol"},{"issue":"16","key":"486_CR16","doi-asserted-by":"publisher","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","volume":"97","author":"SL Hauser","year":"2021","unstructured":"Hauser SL, Kappos L, Montalban X, et al. Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis. Neurology. 2021;97(16):e1546\u201359.","journal-title":"Neurology"},{"issue":"6","key":"486_CR17","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1007\/s13311-023-01415-y","volume":"20","author":"CG Chisari","year":"2023","unstructured":"Chisari CG, Bianco A, Brescia Morra V, et al. Effectiveness of ocrelizumab in primary progressive multiple sclerosis: a multicenter, retrospective, real-world study (OPPORTUNITY). Neurotherapeutics. 2023;20(6):1696\u2013706.","journal-title":"Neurotherapeutics"},{"issue":"2","key":"486_CR18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/ene.15142","volume":"29","author":"L Pontieri","year":"2022","unstructured":"Pontieri L, Blinkenberg M, Bramow S, et al. Ocrelizumab treatment in multiple sclerosis: a Danish population-based cohort study. Eur J Neurol. 2022;29(2):496\u2013504.","journal-title":"Eur J Neurol"},{"issue":"2","key":"486_CR19","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/acn3.51282","volume":"8","author":"E Fernandez-Diaz","year":"2021","unstructured":"Fernandez-Diaz E, Perez-Vicente JA, Villaverde-Gonzalez R, et al. Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population. Ann Clin Transl Neurol. 2021;8(2):385\u201394.","journal-title":"Ann Clin Transl Neurol"},{"issue":"8","key":"486_CR20","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1007\/s10072-024-07449-0","volume":"45","author":"L Lorefice","year":"2024","unstructured":"Lorefice L, Mellino P, Frau J, Coghe G, Fenu G, Cocco E. Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario. Neurol Sci. 2024;45(8):3951\u20139.","journal-title":"Neurol Sci"},{"issue":"8","key":"486_CR21","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1002\/acn3.52118","volume":"11","author":"P Iaffaldano","year":"2024","unstructured":"Iaffaldano P, Lucisano G, Guerra T, et al. A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis. Ann Clin Transl Neurol. 2024;11(8):2008\u201315.","journal-title":"Ann Clin Transl Neurol"},{"key":"486_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105776","volume":"89","author":"M Krbot Skori\u0107","year":"2024","unstructured":"Krbot Skori\u0107 M, Ba\u0161i\u0107 Kes V, Grbi\u0107 N, et al. Ocrelizumab in people with primary progressive multiple sclerosis: a real-world multicentric study. Mult Scler Relat Disord. 2024;89: 105776.","journal-title":"Mult Scler Relat Disord."},{"issue":"4","key":"486_CR23","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s13311-021-01104-8","volume":"18","author":"M Cellerino","year":"2021","unstructured":"Cellerino M, Boffa G, Lapucci C, et al. Predictors of ocrelizumab effectiveness in patients with multiple sclerosis. Neurotherapeutics. 2021;18(4):2579\u201388.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"486_CR24","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s00415-022-11350-1","volume":"270","author":"N Capasso","year":"2023","unstructured":"Capasso N, Palladino R, Cerbone V, et al. Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study. J Neurol. 2023;270(1):272\u201382.","journal-title":"J Neurol"},{"key":"486_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105009","volume":"79","author":"E Alvarez","year":"2023","unstructured":"Alvarez E, Longbrake EE, Rammohan KW, Stankiewicz J, Hersh CM. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management. Mult Scler Relat Disord. 2023;79: 105009.","journal-title":"Mult Scler Relat Disord."},{"issue":"8","key":"486_CR26","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s40263-021-00810-3","volume":"35","author":"N Seery","year":"2021","unstructured":"Seery N, Sharmin S, Li V, et al. Predicting infection risk in multiple sclerosis patients treated with ocrelizumab: a retrospective cohort study. CNS Drugs. 2021;35(8):907\u201318.","journal-title":"CNS Drugs"},{"issue":"4","key":"486_CR27","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1177\/1352458517703801","volume":"24","author":"BV Ineichen","year":"2018","unstructured":"Ineichen BV, Schneider MP, Hlavica M, Hagenbuch N, Linnebank M, Kessler TM. High EDSS can predict risk for upper urinary tract damage in patients with multiple sclerosis. Mult Scler. 2018;24(4):529\u201334.","journal-title":"Mult Scler"},{"key":"486_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102988","volume":"52","author":"NR Oksbjerg","year":"2021","unstructured":"Oksbjerg NR, Nielsen SD, Blinkenberg M, Magyari M, Sellebjerg F. Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases. Mult Scler Relat Disord. 2021;52: 102988.","journal-title":"Mult Scler Relat Disord."},{"issue":"2","key":"486_CR29","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200083","volume":"10","author":"S Ho","year":"2023","unstructured":"Ho S, Oswald E, Wong HK, et al. Ocrelizumab treatment modulates B-cell regulating factors in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10(2): e200083.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"3","key":"486_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s40265-022-01672-9","volume":"82","author":"YN Lamb","year":"2022","unstructured":"Lamb YN. Ocrelizumab: a review in multiple sclerosis. Drugs. 2022;82(3):323\u201334.","journal-title":"Drugs"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00486-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-025-00486-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00486-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T23:08:09Z","timestamp":1750115289000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-025-00486-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["486"],"URL":"https:\/\/doi.org\/10.1007\/s40801-025-00486-x","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"25 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors report no conflicts of interest with respect to the contents of the current study, but note that the patients in the study were treated with a number of disease-modifying drugs and that the authors have received advisory board, membership, and speakers honoraria, travel support, research grants, consulting fees, or clinical trial support from the manufacturers of those drugs, including Actelion, Allergan, Almirall, Alexion, Bayer Schering, Biogen, Celgene, Excemed, Genzyme, Forward Pharma, Ipsen, Medday, Merck, Mylan, Novartis, Sanofi, Roche, and Teva, and their local affiliates.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"The Italian MS Register (RISM) was approved by the Ethics Committee of the \u201cAzienda Ospedaliera\/Universitaria-Policlinico of Bari\u201d (Study REGISTRO SM001, approved on 08\/07\/2016). The study was performed in accordance with the standards of ethics outlined in the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patients signed an informed consent, in line with the Italian MS Register (RISM) rules, that allows the use of clinical data for research purposes.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Anonymized data will be shared on reasonable request from a qualified investigator.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"PI, TG, CF: conception and design of the study, acquisition and analysis of data, drafting the manuscript and figures; DP, AB: data acquisition and drafting a significant portion of the manuscript. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}